Lipitor's Patent Expiration Timeline
Lipitor (atorvastatin), Pfizer's blockbuster statin for cholesterol, lost U.S. patent protection on November 30, 2011, after generating peak annual sales over $12 billion.[1] This ended Pfizer's market exclusivity, allowing generic manufacturers like Ranbaxy, Watson, and Mylan to launch authorized generics and full generics immediately.[2]
Immediate Sales Shift Post-Expiry
Within weeks, generics captured 80% of prescriptions by early 2012, as pharmacies substituted cheaper versions under state laws favoring generics.[1] Pfizer's branded Lipitor sales dropped 85% in the first year, from $5.5 billion in 2011 to under $1 billion by 2013, while total atorvastatin sales grew due to lower prices driving higher volume.[3]
Price Drops That Fueled Volume Surge
Generic prices fell 80-90% almost overnight—from $4+ per pill for branded to under 20 cents for generics.[2] This slashed patient copays, boosting adherence and new prescriptions. U.S. atorvastatin market volume rose 25% within a year, as affordability expanded access beyond insured patients to cash-pay users.[1][3]
Generic Manufacturers' Sales Gains
Ranbaxy alone reported $1 billion in U.S. atorvastatin sales in 2012, its first full generic year.[4] By 2014, multiple generics held 99% market share, with cumulative generic sales exceeding $10 billion annually across producers, directly converting Pfizer's lost revenue.[2]
Why Volume Increased Despite Competition
Lower prices overcame statin "price sensitivity," where high costs deterred use. Generic entry aligned with rising cardiovascular diagnoses, amplifying demand—U.S. prescriptions jumped from 25 million in 2011 to 35 million by 2015.[3] No major efficacy differences between branded and generic atorvastatin supported seamless switching.[1]
Pfizer's Response and Long-Term Impact
Pfizer countered with authorized generics and copay cards, retaining some branded share, but generics dominated.[2] The expiry cut Pfizer's revenue by $100 billion over a decade but saved U.S. payers $150 billion in drug costs, per health economics analyses.[3]
Sources
[1] FDA Orange Book and Patent Expiry Data
[2] DrugPatentWatch.com - Lipitor Patent Details
[3] IMS Health (IQVIA) Sales Reports, 2011-2015
[4] Ranbaxy Annual Report 2012